{
    "SPADE_N_13870": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_N_13870",
            "Peptide Name": "P1 (synthetic AMPs20, fragment of CXCL10, UCLL1)",
            "Source": "Sequence truncation, animal-derived, natural derivative",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "VPLSRTVRCTCISI",
            "Sequence Length": 14,
            "UniProt Entry": "Ref",
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Anti-Gram+",
                "Anti-Gram-",
                "Chemotactic"
            ],
            "Target Organism": "Not found",
            "Hemolytic Activity": "Not found",
            "Cytotoxicity": "Not found",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Not found",
            "N-terminal Modification": "Not found",
            "C-terminal Modification": "Not found",
            "Stereochemistry": "Not found",
            "Structure Description": "Not found",
            "Formula": "Not found",
            "Mass": 1547.88,
            "PI": 9.02,
            "Hydrophobicity": 0.9,
            "Half Life": "Not found",
            "Function": "Not found",
            "Literature": [
                {
                    "Author": "Crawford MA, Ward AE, Gray V, Bailer P, Fisher DJ, Kubicka E, Cui Z, Luo Q, Gray MC, Criss AK, Lum LG, Tamm LK, Letteri RA, Hughes MA. 2022",
                    "Reference": "ACS Infect Dis. 2022 Dec 7. doi: 10.1021/acsinfecdis.2c00456.PubMed",
                    "Title": "Disparate Regions of the Human Chemokine CXCL10 Exhibit Broad-Spectrum Antimicrobial Activity against Biodefense and Antibiotic-Resistant Bacterial Pathogens."
                }
            ],
            "Frequent Amino Acids": "CIR",
            "Absent Amino Acids": "ADEFGHKMNOQUWY",
            "Basic Residues": 2,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 6,
            "Polar Residues": 10,
            "Positive Residues": 2,
            "Negative Residues": 0,
            "Net Charge": 2,
            "Comments": "Sequence analysis: APD analysis reveals this sequence is most similar (46.67%) tofrog Odorranain-V1A peptide corresponding to the N-terminal 14 amino acids of human CXCL10 (see AP02080). I=V=C=T=S=R=R: 14%. GRAVY: 0.9; M Wt: 1547.91; Mol formula: C65H118N20O19S2; Mol ex coeff: 125.Activity: P1 kills B. anthracis Sterne 7702 bacilli (EC50 18.1 uM), B. anthracis bacilli lacking the FtsX component of the FtsE/X complex (EC50 53.1 uM), B. subtilis 168, Gram-negative K. pneumoniae NDM-1 clinical isolate BL13802, K. pneumoniae BL13802 at 50 uM, reduced the viability of A. baumannii, P. aeruginosa, E. cloacae, S. typhi, N. gonorrhoeae, E. coli clinical isolate FI-4531 that expresses mcr-1, S. faecium, and S. aureus at 5. 6 uM. It also inhibited the dormant and hardy spore form of B. anthracis. It also showed minimal chemotactic activity at 50 uM, much less effective than the parent CXCL10.Structure: it is random coil in Kph buffer-only or 50% TFE, but became beta-sheet (positive at 192 nm and negative at 220 nm) in liposomes that mimic bacterial membranes. This sequence appears to be improtant for killing since a sequence scrambled peptide was not bactericidal.Updated 12/2024",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_03117",
                    "Similarity": 1.0,
                    "Sequence": "VPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPRVEIIATMKKKGEKRCLNPESKAIKNLLKAVSKERSKRSP"
                },
                {
                    "SPADE_ID": "SPADE_N_00180",
                    "Similarity": 0.7142857142857143,
                    "Sequence": "RCTCTTIISSSSTF"
                },
                {
                    "SPADE_ID": "SPADE_UN_06691",
                    "Similarity": 0.6,
                    "Sequence": "VYILILFICIFLVMIVCDSAYLPLSRSCITDKDCSRVKNYNARCRKGYCQYLQY"
                }
            ]
        }
    }
}